Clinical Trial Update: Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing tarlatamab (AMG 757) in metastatic/locally advanced small-cell lung cancer and other poorly differentiated neuroendocrin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma
• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC | Phase 2 | Status: RECRUITING